ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead Acquires Phenex Program

by Ann M. Thayer
January 12, 2015 | APPEARED IN VOLUME 93, ISSUE 2

Gilead Sciences is acquiring a liver disease drug development program from the privately held German company Phenex Pharmaceuticals. Gilead will pay up to $470 million for Phenex’s small-molecule farnesoid X receptor (FXR) agonists. FXR is a nuclear hormone receptor that regulates bile acid, lipid, and glucose homeostasis, which can help reduce liver steatosis and inflammation and may help prevent liver fibrosis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment